Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia.
Humans
Sorafenib
/ therapeutic use
Phenylurea Compounds
/ adverse effects
Transplantation, Homologous
Retrospective Studies
Niacinamide
/ therapeutic use
Hematopoietic Stem Cell Transplantation
/ adverse effects
Leukemia, Myeloid, Acute
/ therapy
Recurrence
fms-Like Tyrosine Kinase 3
/ genetics
Mutation
Acute myeloid leukemia
FLT3–ITD mutation
Hematopoietic stem cell transplantation
Sorafenib maintenance
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
19
04
2022
accepted:
20
07
2022
revised:
20
07
2022
pubmed:
10
8
2022
medline:
22
11
2022
entrez:
9
8
2022
Statut:
ppublish
Résumé
In a retrospective analysis, 21 acute myeloid leukemia patients receiving single-agent sorafenib maintenance therapy in complete remission (CR) after hematopoietic stem cell transplantation (HSCT) were compared with a control group of 22 patients without maintenance. Sorafenib was initiated a median of 3 months (IQR: 2.3-3.5) after allogeneic HSCT with a median daily dosage of 400 mg (range: 200-800) orally, and lasted a median of 11.3 months (IQR: 3.3-24.4). No significant increase in graft versus host disease or toxicity was observed. Adverse events were reversible with dose adjustment or temporary discontinuation in 19/19 cases. With a median follow-up of 34.7 months (IQR: 16.9-79.5), sorafenib maintenance significantly improved cumulative incidence of relapse (p = 0.028) as well as overall survival (OS) (p = 0.016), especially in patients undergoing allogeneic HSCT in CR1 (p < 0.001). In conclusion, sorafenib maintenance after allogeneic HSCT is safe and may improve cumulative incidence of relapse and OS in FLT3-ITD-mutated AML.
Identifiants
pubmed: 35943684
doi: 10.1007/s12185-022-03427-4
pii: 10.1007/s12185-022-03427-4
pmc: PMC9668769
doi:
Substances chimiques
Sorafenib
9ZOQ3TZI87
Phenylurea Compounds
0
Niacinamide
25X51I8RD4
fms-Like Tyrosine Kinase 3
EC 2.7.10.1
FLT3 protein, human
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
883-891Informations de copyright
© 2022. The Author(s).
Références
Blood. 2015 Oct 22;126(17):2062-9
pubmed: 26351297
Blood. 2009 Jun 25;113(26):6567-71
pubmed: 19389879
J Clin Oncol. 2005 Oct 20;23(30):7583-93
pubmed: 16234522
N Engl J Med. 2019 Oct 31;381(18):1728-1740
pubmed: 31665578
Med Oncol. 2017 Jun;34(6):114
pubmed: 28470536
Blood. 2019 Feb 21;133(8):840-851
pubmed: 30563875
Biol Blood Marrow Transplant. 2014 Dec;20(12):2042-8
pubmed: 25239228
Blood. 1992 Sep 1;80(5):1199-206
pubmed: 1381238
Leukemia. 2017 Jan;31(1):26-33
pubmed: 27416910
Am J Med. 1980 Aug;69(2):204-17
pubmed: 6996481
Blood. 2011 Mar 24;117(12):3286-93
pubmed: 21263155
Blood. 2010 Oct 14;116(15):2858-9
pubmed: 20947691
Blood. 2014 Nov 27;124(23):3441-9
pubmed: 25270908
Eur J Haematol. 2001 Jun;66(6):365-76
pubmed: 11488935
Clin Hematol Int. 2019 Mar 18;1(1):58-74
pubmed: 34595412
Lancet Oncol. 2020 Sep;21(9):1201-1212
pubmed: 32791048
Leukemia. 2012 Nov;26(11):2353-9
pubmed: 22504140
Eur J Cancer. 2017 Nov;86:233-239
pubmed: 29055209
J Clin Oncol. 2020 Sep 10;38(26):2993-3002
pubmed: 32673171
Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):506-508
pubmed: 31122828
Bone Marrow Transplant. 2021 Dec;56(12):3091-3093
pubmed: 34584238
Blood. 2011 Mar 24;117(12):3294-301
pubmed: 21270442
Cancer. 2017 Aug 1;123(15):2867-2874
pubmed: 28387928
Sci Transl Med. 2020 Oct 28;12(567):
pubmed: 33115954
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Nat Med. 2018 Mar;24(3):282-291
pubmed: 29431743
Blood. 1997 Mar 15;89(6):1870-5
pubmed: 9058706
Biol Blood Marrow Transplant. 2011 Sep;17(9):1404-9
pubmed: 21324374
Bone Marrow Transplant. 2019 Sep;54(9):1518-1520
pubmed: 30809038
Blood. 2002 Jun 15;99(12):4326-35
pubmed: 12036858
N Engl J Med. 2017 Aug 3;377(5):454-464
pubmed: 28644114